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SUPPLEMENTARY DATA 
Search strategy 
A systematic search was undertaken using PubMed and the Cochrane Database of Systematic Reviews to 
find original papers and systematic reviews with or without meta-analysis in the English language using the 
terms shown below in the supplementary table S1. The questions about the management of lupus developed 
by the guideline development group to be addressed by the literature review were: 
i) What clinical and serological features should prompt consideration of a diagnosis of SLE? 
ii) How should SLE patients be assessed? 
iii) How should SLE patients be monitored in the non-acute setting?   
iv) What is the evidence for the management of mild SLE? 
v) What is the evidence for the management of moderate SLE? 
vi) What is the evidence for the management of severe SLE? 
 
Papers covering purely animal studies, pediatric studies, narrative review articles (except systematic 
reviews), commentaries, conference abstracts or statements, expert opinion statements and other guidelines 
were excluded (although such papers were checked manually for additional relevant references). We only 
reviewed papers that included the following numbers of patients (with search terms as described below): 
background, prevalence &  prognosis a minimum 50 SLE patients, for diagnosis, assessment & monitoring a 
minimum 10 patients, for therapy a minimum 5 patients. Papers meeting these selection criteria were graded 
according to the SIGN revised grading system for recommendations in evidence based guidelines as shown 
in supplementary .table S 2 (1). 
 Supplementary table S1: Search terms used in PubMed and Cochrane Database of Systematic 
Reviews for the literature review 
1. Section of 
guideline 
Topic 
– Search terms used in addition to SLE OR 
Systemic Lupus Erythematosus OR Lupus 




– Clinical manifestations/ Manifestations 






– Anti-nuclear antibodies, ANA, anti-dsDNA, anti-Ro, 
anti-Sm, C3, C4, anti-phospholipid, antiphospholipid, 
anti-cardiolipin, anticardiolipin, lupus anticoagulant 
 Lupus manifestations 
including differences 
between lupus in males and 
females 
– SLE activity 
– Disease Damage 
– Mortality  
– Presentation 
– Outcome  
– ACR classification criteria 
– Malar rash 
– Discoid Rash 
– Photosensitivity 
– Oral Ulcers 
– Nonerosive arthritis 
– Pleuritis OR Pericarditis 
– Proteinuria OR Cellular casts 
– Neuropsychiatric 
– Haemolytic anaemia OR Leucopenia/Leukopenia OR 
Lymphopenia OR Thrombocytopenia 
– anti-double stranded DNA OR anti-Sm OR 
antiphospholipid antibodies OR anti-phospholipid 
antibodies OR ANA 
– +/-  gender differences 






All above  items AND  
Assess/ assessment 






 Neuro-psychiatric  
disease 
Neuropsychiatric AND  
– Prevalence 







Cancer OR Malignancy AND 
– Mortality 
– Lymphoma 







Infection Risk AND/OR 
– Death 
– Antibiotic prophylaxis 
– vaccin* 
–  Bacteria*  Infections 
– CMV 
– HPV 
– Varicella Zoster virus 
– Hepatitis B AND C 
– Hepatitis vaccin* 
– Pneumocystis jiroveci 

























Treatment or therapy or trial or study or management) 
AND 
Therapy NAME AND/OR  
- Mild or Moderate or Severe 
- Activity or damage or flare 
- BILAG or SLEDAI or ECLAM or SLAM or disease 
activity index  
- Efficacy or safety or outcome 
- Non-renal 
- Constitutional 
- Rash or mucocutaneous or dermatol* 
- Vasculitis 
- Arthritis or musculoskeletal 
- Cardiac or respiratory or cardio-respiratory or gastro-
intestinal 
- Neuro-psychiatric or neuro* 
 Supplementary table S2: SIGN revised grading system for recommendations in evidence based 
guidelines 
SIGN Levels of evidence SIGN Grades of recommendations 
1++ High quality meta-analyses, 
systematic reviews of RCTs, or RCTs 
with a very low risk of bias 
1+  Well conducted meta-analyses, 
systematic reviews of RCTs, or RCTs 
with a low risk of bias 
1−  Meta-analyses, systematic reviews or 
RCTs, or RCTs with a high risk of bias 
2++  High quality systematic reviews of 
case-control or cohort studies or 
      High quality case-control or cohort 
studies with a very low risk of 
confounding, bias, or chance and a high 
probability that the relationship is causal 
2+  Well conducted case-control or cohort 
studies with a low risk of confounding, 
bias, or chance and a moderate 
probability that the relationship is causal 
2−  Case-control or cohort studies with a 
high risk of confounding, bias, or chance 
and a significant risk that the relationship 
is not causal 
3  Non-analytic studies, e.g. case reports, 
case series 
4  Expert opinion 
A  At least one meta-analysis, systematic 
review, or RCT rated as 1++ and directly 
applicable to the target population or 
      a systematic review of RCTs or a body of 
evidence consisting principally of studies 
rated as 1+ directly applicable to the target 
population and demonstrating overall 
consistency of results 
B  A body of evidence including studies rated as 
2++ directly applicable to the target 
population and demonstrating overall 
consistency of results or 
      Extrapolated evidence from studies rated as 
1++ or 1+ 
C  A body of evidence including studies rated as 
2+ directly applicable to the target population 
and demonstrating overall consistency of 
results or 
      Extrapolated evidence from studies rated as 
2++ 
D  Evidence level 3 or 4 or 
      Extrapolated evidence from studies rated as 
2+ 
 
Reproduced from A new system for grading recommendations in evidence based guidelines, 
Harbour R, Miller J, 323, 334-6, 2001withpermission from BMJ Publishing Group Ltd [1].  
 Supplementary Table S3: Cumulative incidence of SLE manifestations in lupus cohorts 
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a combined incidence for items with same value. bconfirmed arthritis only (usually non-erosive). call 
neurological features associated with lupus combined. dpossible failure of ascertainment but patients met ≥4 
ACR criteria. ecombined as met ACR criteria for immunological involvement. - not reported.
BILAG-2004 Index data collection form.  Date:      No: 
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 Record: ND     Not Done 
                0       Not present 
                1       Improving 
                2       Same 
                3       Worse 
                4       New 
              Yes/No OR Value   (where indicated) 
             Y/N   Confirm this is due to SLE activity (Yes/No) 
 
CONSTITUTIONAL 
1. Pyrexia - documented > 37.5ºC      (     ) 
2. Weight loss - unintentional > 5%      (     ) 
3. Lymphadenopathy/splenomegaly      (     ) 
4. Anorexia        (     ) 
 
MUCOCUTANEOUS 
5. Skin eruption - severe       (     ) 
6. Skin eruption - mild       (     ) 
7. Angio-oedema - severe       (     ) 
8. Angio-oedema - mild       (     ) 
9. Mucosal ulceration - severe      (     ) 
10. Mucosal ulceration - mild       (     ) 
11. Panniculitis/Bullous lupus - severe      (     ) 
12. Panniculitis/Bullous lupus - mild      (     ) 
13. Major cutaneous vasculitis/thrombosis     (     ) 
14. Digital infarcts or nodular vasculitis     (     ) 
15. Alopecia - severe       (     ) 
16. Alopecia - mild        (     ) 
17. Peri-ungual erythema/chilblains      (     ) 
18. Splinter haemorrhages       (     ) 
 
NEUROPSYCHIATRIC 
19. Aseptic meningitis       (     ) 
20. Cerebral vasculitis       (     ) 
21. Demyelinating syndrome       (     ) 
22. Myelopathy        (     ) 
23. Acute confusional state       (     ) 
24. Psychosis        (     ) 
25. Acute inflammatory demyelinating      (     ) 
       polyradiculoneuropathy 
26. Mononeuropathy (single/multiplex)      (     ) 
27. Cranial neuropathy       (     ) 
28. Plexopathy        (     ) 
29. Polyneuropathy        (     ) 
30. Seizure disorder       (     ) 
31. Status epilepticus       (     ) 
32. Cerebrovascular disease (not due to vasculitis)    (     )  
33. Cognitive dysfunction       (     ) 
34. Movement disorder       (     ) 
35. Autonomic disorder       (     ) 
36. Cerebellar ataxia (isolated)      (     ) 
37. Lupus headache - severe unremitting      (     ) 
38. Headache from IC hypertension      (     ) 
 
MUSCULOSKELETAL 
39. Myositis - severe       (     ) 
40. Myositis - mild        (     ) 
41. Arthritis ( severe)       (     ) 
42. Arthritis (moderate)/Tendonitis/Tenosynovitis    (     ) 








44. Myocarditis - mild   ( ) 
45. Myocarditis/Endocarditis + Cardiac failure ( ) 
46. Arrhythmia    ( ) 
47. New valvular dysfunction   ( ) 
48. Pleurisy/Pericarditis   ( ) 
49. Cardiac tamponade   ( ) 
50. Pleural effusion with dyspnoea  ( ) 
51. Pulmonary haemorrhage/vasculitis  ( ) 
52. Interstitial alveolitis/pneumonitis  ( ) 
53. Shrinking lung syndrome   ( ) 
54. Aortitis    ( ) 
55. Coronary vasculitis   ( ) 
 
GASTROINTESTINAL 
56. Lupus peritonitis   ( ) 
57. Abdominal serositis or ascites  ( ) 
58. Lupus enteritis/colitis   ( ) 
59. Malabsorption    ( ) 
60. Protein losing enteropathy  ( ) 
61. Intestinal pseudo-obstruction  ( ) 
62. Lupus hepatitis    ( ) 
63. Acute lupus cholecystitis   ( ) 
64. Acute lupus pancreatitis   ( ) 
 
OPHTHALMIC 
65. Orbital inflammation/myositis/proptosis ( ) 
66. Keratitis - severe   ( ) 
67. Keratitis - mild    ( ) 
68. Anterior uveitis    ( ) 
69. Posterior uveitis/retinal vasculitis - severe ( ) 
70. Posterior uveitis/retinal vasculitis - mild ( ) 
71. Episcleritis    ( ) 
72. Scleritis - severe   ( ) 
73. Scleritis - mild    ( ) 
74. Retinal/choroidal vaso-occlusive disease ( ) 
75. Isolated cotton-wool spots (cytoid bodies) ( ) 
76. Optic neuritis    ( ) 
77. Anterior ischaemic optic neuropathy ( ) 
 
RENAL  
78. Systolic blood pressure (mm Hg)   value ( ) Y/N 
79. Diastolic blood pressure (mm Hg)   value ( ) Y/N 
80. Accelerated hypertension                   Yes/No ( )   
81. Urine dipstick protein    (+=1, ++=2, +++=3) ( ) Y/N 
82. Urine albumin-creatinine ratio         mg/mmol ( ) Y/N 
83. Urine protein-creatinine ratio           mg/mmol ( ) Y/N 
84. 24 hour urine protein (g)    value ( ) Y/N 
85. Nephrotic syndrome     Yes/No ( )   
86. Creatinine (plasma/serum)   mol/l ( ) Y/N 
87. GFR (calculated)                     ml/min/1.73 m2 ( ) Y/N 
88. Active urinary sediment                     Yes/No ( )   
89. Active nephritis     Yes/No ( )   
 
HAEMATOLOGICAL 
90. Haemoglobin (g/dl)    value ( ) Y/N 
91. Total white cell count (x 109/l)   value ( ) Y/N 
92. Neutrophils (x 109/l)    value ( ) Y/N 
93. Lymphocytes (x 109/l)    value ( ) Y/N 
94. Platelets (x 109/l)    value ( ) Y/N 
95. TTP       ( ) 
96. Evidence of active haemolysis          Yes/No ( ) 
97. Coombs’ test positive (isolated)  Yes/No ( ) 
 Only record manifestations/items due to SLE Disease Activity  
 Assessment refers to manifestations occurring in the last 4 weeks (compared with the previous 4 weeks) 
 TO BE USED WITH THE GLOSSARY  
                         
 
Weight (kg):    Serum urea (mmol/l): 
African ancestry:  Yes/No      Serum albumin (g/l): 
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      only record features that are attributable to SLE disease activity and not due to  
        damage, infection, thrombosis (in absence of inflammatory process) or other  
        conditions 
 
      assessment refers to manifestations occurring in the last 4 weeks compared with the  
        previous 4 weeks 
 
      activity refers to disease process which is reversible while damage refers to permanent  
        process/scarring (irreversible) 
 
      damage due to SLE should be considered as a cause of features that are fixed/persistent  
        (SLICC/ACR damage index uses persistence  6 months to define damage) 
 
      in some manifestations, it may be difficult to differentiate SLE from other conditions as  
        there may not be any specific test and the decision would then lies with the physician’s  
        judgement on the balance of probabilities 
 
      ophthalmic manifestations usually need to be assessed by an ophthalmologist and these  
        items would need to be recorded after receiving the response from the ophthalmologist 
 
      guidance for scoring: 
 
          (4) NEW  
                  manifestations are recorded as new when it is a new episode occurring in the last   
                    4 weeks (compared to the previous 4 weeks) that has not improved and this  
                    includes new episodes (recurrence) of old manifestations  
 
                  new episode occurring in the last 4 weeks but also satisfying the criteria for     
                    improvement (below) would be classified as improving instead of new 
 
          (3) WORSE 
                  this refers to manifestations that have deteriorated/worsened significantly in the  
                    last 4 weeks compared to the previous 4 weeks, sufficient for consideration of  
                    increase in therapy 
 
          (2) SAME 
                  this refers to manifestations that have been present for the last 4 weeks and the  
                    previous 4 weeks without significant improvement or deterioration (from the  
                    previous 4 weeks) 
 
                  this also applies to manifestations that have improved over the last 4 weeks  
                    compared to the previous 4 weeks but do not meet the criteria for improvement 
 
 
           




                  definition of improvement: (a) the amount of improvement is sufficient for  
                       consideration of reduction in therapy and  
                                                                       would not justify escalation in therapy 
 
AND   
               
                                                                 (b) improvement must be present currently and 
                                                                       for at least 2 weeks out of the last 4 weeks 
 
                                                                        OR 
 
                                                                      manifestation that has completely resolved and  
                                                                      remained absent over the whole of last 1 week 
 
          (0) NOT PRESENT 
 
          (ND) NOT DONE 
                  it is important to indicate if a test has not been performed (particularly laboratory  
                    investigations) so that this will be recorded as such in the database & not as  
                    normal or absent (which is the default) 
 
           INDICATE (TICK) IF NOT DUE TO SLE ACTIVITY 
                  for descriptors that are based on measurements (in renal and haematology  
                    systems), it is important to indicate if these are not due to lupus disease activity  
                    (for consideration of scoring) as they are usually recorded routinely into a  
                    database 
 
          CHANGE IN SEVERITY CATEGORY 
                  there are several items in the index which have been divided into categories of  
                    mild and severe (depending on definition). It is essential to record mild and  
                    severe items appropriately if the manifestations fulfil both criteria during the last  
                    4 weeks 
 
                  if a mild item deteriorated to the extent that it fulfilled the definition of severe  
                    category (ie changed into severe category) within the last 4 weeks: 
       severe item scored as new (4)  
                    AND  mild item scored as worsening (3) 
 
                  if a severe item improved (fulfilling the improvement criteria) to the extent that it  
                    no longer fulfilled the definition of severe category (ie changed into mild  
                    category) within the last 4 weeks: 
                               severe item scored as not present (0) if criteria for severe category has not  
                                                                                              been met over last 4 weeks 
                                                         or as improving (1) if criteria for severe category has been                  
                                                                                             met at some point over last 4 weeks 
                   AND  
                               mild item scored as improving (1) if it is improving over last 4 weeks 
                                                      or as the same (2) if it has remained stable over last 4 weeks 





1. Pyrexia      temperature > 37.5˚C documented 
 
2. Unintentional weight loss > 5% 
3. Lymphadenopathy    lymph node more than 1 cm diameter 
 
      exclude infection 






5. Severe eruption     > 18% body surface area 
                         
any lupus rash except panniculitis, bullous lesion  
& angio-oedema 
 
body surface area (BSA) is estimated using the 
rules of nines (used to assess extent of burns) (9) as 
follows: 
 
palm(excluding fingers) = 1% BSA 
            each lower limb = 18% BSA 
              each upper limb = 9% BSA 
               torso (front) = 18% BSA 
               torso (back) = 18% BSA 
               head = 9% BSA 
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6. Mild eruption     ≤ 18% body surface area 
                                 
any lupus rash except panniculitis, bullous lesion  
& angio-oedema 
 
malar rash must have been observed by a  
physician and has to be present continuously  
(persistent) for at least 1 week to be considered  
significant (to be recorded) 
 
7. Severe angio-oedema    potentially life-threatening eg: stridor 
 
      angio-oedema is a variant form of urticaria  
                                                                        which affects the subcutaneous, submucosal and  
deep dermal tissues 
 
8. Mild angio-oedema    not life threatening 
 
9. Severe mucosal ulceration   disabling (significantly interfering with oral  
                                                                        intake), extensive & deep ulceration 
       
      must have been observed by a physician 
 
10. Mild mucosal ulceration   localised &/or non-disabling ulceration 
 
11. Severe panniculitis or bullous lupus any one: 
> 9% body surface area 
facial  panniculitis 
     panniculitis that is beginning to ulcerate 
     panniculitis that threatens integrity of  
       subcutaneous tissue (beginning to cause   
       surface depression) on > 9% body surface  
       area 
 
      panniculitis presents as a palpable and tender  
subcutaneous induration/nodule  
 
note that established surface depression and  
atrophy alone is likely to be due to damage 
 
12. Mild panniculitis or bullous lupus ≤ 9% body surface area   
does not fulfil any criteria for severe panniculitis 
(for panniculitis) 
 
13. Major cutaneous vasculitis/thrombosis resulting in extensive gangrene or ulceration or  
skin infarction 
 
14. Digital infarct or nodular vasculitis localised single or multiple infarct(s) over  
digit(s) or tender erythematous nodule(s) 
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15. Severe alopecia    clinically detectable (diffuse or patchy) hair loss  
with scalp inflammation (redness over scalp) 
 
16. Mild alopecia diffuse or patchy hair loss without scalp 
inflammation (clinically detectable or by history) 
 
17. Peri-ungual erythema or chilblains chilblains are localised inflammatory lesions  
                                                                        (may ulcerate) which are precipitated by  
exposure to cold 
 





19. Aseptic meningitis   criteria (all): acute/subacute onset 
           headache 
       fever 
     abnormal CSF (raised protein &/or  
       lymphocyte predominance) but negative  
       cultures 
 
preferably photophobia, neck stiffness and  
meningeal irritation should be present as well but  
are not essential for diagnosis 
     
 exclude CNS/meningeal infection, intracranial    
haemorrhage 
 
20. Cerebral vasculitis   should be present with features of vasculitis  
in another system  
 
supportive imaging &/or biopsy findings 
 
21. Demyelinating syndrome   discrete white matter lesion with associated   
       neurological deficit not recorded elsewhere 
 
ideally there should have been at least one 
previously recorded event 
 
supportive imaging required 
 
exclude multiple sclerosis 
 
22. Myelopathy    acute onset of rapidly evolving paraparesis or  
quadriparesis and/or sensory level 
 
exclude intramedullary and extramedullary  
space occupying lesion 
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23. Acute confusional state   acute disturbance of consciousness or level of  
arousal with reduced ability to focus, maintain or 
shift attention 
 
includes hypo- and hyperaroused states and 
encompasses the spectrum from delirium to coma 
 
24. Psychosis     delusion or hallucinations    
 
      does not occur exclusively during course of a  
delirium 
 
exclude drugs, substance abuse, primary  
psychotic disorder 
 
25. Acute inflammatory demyelinating criteria: 
       polyradiculoneuropathy       progressive polyradiculoneuropathy 
          loss of reflexes 
          symmetrical involvement 
          increased CSF protein without pleocytosis 
    supportive electrophysiology study 
 
26. Mononeuropathy (single/multiplex) supportive electrophysiology study required 
 
27. Cranial neuropathy   except optic neuropathy which is classified  
under ophthalmic system 
 
28. Plexopathy    disorder of brachial or lumbosacral plexus  
resulting in neurological deficit not  
corresponding to territory of single root or nerve 
 
supportive electrophysiology study required 
 
29. Polyneuropathy    acute symmetrical distal sensory and/or motor  
                                                                        deficit 
 
      supportive electrophysiology study required 
 
30. Seizure disorder independent description of seizure by reliable 
witness 
 
31. Status epilepticus    a seizure or series of seizures lasting ≥ 30  
minutes without full recovery to baseline 
 
32. Cerebrovascular disease   any one with supporting imaging: 
       (not due to vasculitis)      stroke syndrome 
         transient ischaemic attack 
         intracranial haemorrhage 
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exclude hypoglycaemia, cerebral sinus thrombosis, 
vascular malformation, tumour, abscess 
 
cerebral sinus thrombosis not included as  
definite thrombosis not considered part of lupus 
activity 
 
33. Cognitive dysfunction   significant deficits in any cognitive functions: 
         simple attention (ability to register & maintain  
                                                                             information) 
         complex attention 
         memory (ability to register, recall & recognise  
                                                                             information eg learning, recall) 
         visual-spatial processing (ability to analyse,  
                                                                             synthesise & manipulate visual-spatial  
                                                                             information) 
         language (ability to comprehend, repeat &  
                                                                             produce oral/written material eg verbal  
                                                                             fluency, naming) 
         reasoning/problem solving (ability to reason &  
                                                                             abstract) 
         psychomotor speed 
         executive functions (eg planning, organising,  
                                                                             sequencing) 
 
      in absence of disturbance of consciousness or  
level of arousal 
       
      sufficiently severe to interfere with daily  
activities 
     
 neuropsychological testing should be done or  
corroborating history from third party if possible  
 
      exclude substance abuse 
 
34. Movement disorder   exclude drugs 
 
35. Autonomic disorder   any one: 
         fall in blood pressure to standing > 30/15 mm  
   Hg (systolic/diastolic) 
 
   increase in heart rate to standing ≥ 30 bpm 
 
   loss of heart rate variation with respiration   
   (max – min < 15 bpm, expiration:inspiration  
   ratio < 1.2, Valsalva ratio < 1.4) 
 
   loss of sweating over body and limbs  
   (anhidrosis) by sweat test 




      exclude drugs and diabetes mellitus 
 
36. Cerebellar ataxia cerebellar ataxia in isolation of other CNS features 
 
 usually subacute presentation 
 
37. Severe lupus headache (unremitting) disabling headache unresponsive to narcotic 
analgesia & lasting ≥ 3 days 
 
exclude intracranial space occupying lesion  
and CNS infection 
 





39. Severe myositis    significantly elevated serum muscle enzymes  
       with significant muscle weakness 
 
      exclude endocrine causes and drug-induced  
       myopathy 
 
electromyography and muscle biopsy are used for 
diagnostic purpose and are not required to 
determine level of activity 
 
40. Mild myositis    significantly elevated serum muscle enzymes  
with myalgia but without significant muscle  
weakness 
 
      asymptomatic elevated serum muscle enzymes  
not included 
 
exclude endocrine causes and drug-induced  
       myopathy 
 
electromyography and muscle biopsy are used for 
diagnostic purpose and are not required to 
determine level of activity 
 
41. Severe arthritis    observed active synovitis ≥ 2 joints with marked   
                                                                        loss of functional range of movements and  
                                                                        significant impairment of activities of daily  
                                                                        living, that has been present on several days  
                                                                        (cumulatively) over the last 4 weeks 
 
42. Moderate arthritis or Tendonitis tendonitis/tenosynovitis or active synovitis ≥ 1  
 From Yee et al. Numerical scoring for the BILAG-2004 index Rheumatology (2010) 49 (9): 1665-1669 
[8].  
 
       or Tenosynovitis  joint (observed or through history) with some loss 
of functional range of movements, that has been 
present on several days over the last 4 weeks 
 
43. Mild arthritis or Arthralgia or Myalgia inflammatory type of pain (worse in the morning 
with stiffness, usually improves with activity & not 
brought on by activity) over joints/muscle  
 
inflammatory arthritis which does not fulfil the 





44. Mild myocarditis    inflammation of myocardium with raised  
cardiac enzymes &/or ECG changes and without 
resulting cardiac failure, arrhythmia or valvular 
dysfunction 
 
45. Cardiac failure cardiac failure due to myocarditis or non-infective 
inflammation of endocardium or cardiac valves 
(endocarditis) 
 
 cardiac failure due to myocarditis is defined by left 
ventricular ejection fraction ≤ 40% & pulmonary 
oedema or peripheral oedema 
 
cardiac failure due to acute valvular regurgitation 
(from endocarditis) can be associated with normal 
left ventricular ejection fraction 
 
 diastolic heart failure is not included 
 
46. Arrhythmia arrhythmia (except sinus tachycardia) due to 
myocarditis or non-infective inflammation of 
endocardium or cardiac valves (endocarditis) 
 
      confirmation by electrocardiogram required  
(history of palpitations alone inadequate) 
 
47. New valvular dysfunction new cardiac valvular dysfunction due to 
myocarditis or non-infective inflammation of 
endocardium or cardiac valves (endocarditis) 
 
      supportive imaging required 
 
48. Pleurisy/Pericarditis convincing history &/or physical findings that you 
would consider treating 
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 in absence of cardiac tamponade or pleural effusion 
with dyspnoea 
 
                                                                        do not score if you are unsure whether or not it is 
pleurisy/pericarditis 
 
49. Cardiac tamponade   supportive imaging required 
50. Pleural effusion with dyspnoea  supportive imaging required 
51. Pulmonary haemorrhage/vasculitis inflammation of pulmonary vasculature with  
haemoptysis &/or dyspnoea &/or pulmonary 
hypertension 
 
supportive imaging &/or histological diagnosis 
required 
 
52. Interstitial alveolitis/pneumonitis  radiological features of alveolar infiltration not  
due to infection or haemorrhage required for 
diagnosis 
 
corrected gas transfer Kco reduced to < 70% 
normal or fall of > 20% if previously abnormal 
 
      on-going activity would be determined by  
clinical findings and lung function tests, and  
repeated imaging may be required in those with  
deterioration (clinically or lung function tests) or 
failure to respond to therapy 
 
53. Shrinking lung syndrome   acute reduction (> 20% if previous measurement  
                                                                        available) in lung volumes (to < 70% predicted)  
                                                                        in the presence of normal corrected gas transfer  
                                                                        (Kco) & dysfunctional diaphragmatic  
movements 
 
54. Aortitis     inflammation of aorta (with or without  
dissection) with supportive imaging abnormalities  
 
accompanied by > 10 mm Hg difference in BP 
between arms &/or claudication of extremities &/or 
vascular bruits 
 
      repeated imaging would be required to determine  
on-going activity in those with clinical  
deterioration or failure to respond to therapy 
 
55. Coronary vasculitis   inflammation of coronary vessels with  
radiographic evidence of non-atheromatous 
narrowing, obstruction or aneurysmal changes 
GASTROINTESTINAL 
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56. Lupus peritonitis    serositis presenting as acute abdomen with  
rebound/guarding 
 
57. Serositis     not presenting as acute abdomen 
 
58. Lupus enteritis or colitis vasculitis or inflammation of small or large bowel 
with supportive imaging &/or biopsy findings 
 
59. Malabsorption    diarrhoea with abnormal D- xylose absorption  
test or increased faecal fat excretion after exclusion 
of coeliac’s disease (poor response to gluten-free 
diet) and gut vasculitis 
 
60. Protein-losing enteropathy  diarrhoea with hypoalbuminaemia or increased  
faecal excretion of iv radiolabeled albumin after 
exclusion of gut vasculitis and malabsorption 
 
61. Intestinal pseudo-obstruction  subacute intestinal obstruction due to intestinal  
hypomotility 
 
62. Lupus hepatitis    raised transaminases  
 
absence of autoantibodies specific to autoimmune 
hepatitis (eg: anti-smooth muscle, anti-liver cytosol 
1) &/or biopsy appearance of chronic active 
hepatitis 
 
hepatitis typically lobular with no piecemeal 
necrosis 
 
exclude drug-induced and viral hepatitis 
 
63. Acute lupus cholecystitis   after exclusion of gallstones and infection 
 





65. Orbital inflammation   orbital inflammation with myositis &/or extra- 
ocular muscle swelling &/or proptosis 
 
      supportive imaging required 
 
66. Severe keratitis     sight threatening 
includes:  corneal melt 
    peripheral ulcerative keratitis 
 
67. Mild keratitis    not sight threatening 
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68. Anterior uveitis 
69. Severe posterior uveitis &/or retinal  sight-threatening &/or retinal vasculitis 
       vasculitis     not due to vaso-occlusive disease 
 
70. Mild posterior uveitis &/or retinal not sight-threatening 
       vasculitis       
not due to vaso-occlusive disease 
 
71. Episcleritis 
72. Severe scleritis    necrotising anterior scleritis 
     
 anterior &/or posterior scleritis requiring  
systemic steroids/immunosuppression &/or not 
responding to NSAIDs 
 
73. Mild scleritis anterior &/or posterior scleritis not requiring 
systemic steroids 
       
      excludes necrotising anterior scleritis 
 
74. Retinal/choroidal vaso-occlusive   includes: retinal arterial & venous occlusion 
disease         serous retinal &/or retinal pigment  
     epithelial detachments secondary to    
     choroidal vasculopathy 
 
75. Isolated cotton-wool spots  also known as cytoid bodies   
 
76. Optic neuritis    excludes anterior ischaemic optic neuropathy 
 
77. Anterior ischaemic optic neuropathy visual loss with pale swollen optic disc due to 





78. Systolic blood pressure 
79. Diastolic blood pressure 
80. Accelerated hypertension   blood pressure rising to > 170/110 mm Hg  
within 1 month with grade 3 or 4 Keith-Wagener-
Barker retinal changes (flame-shaped haemorrhages 
or cotton-wool spots or papilloedema) 
 
81. Urine dipstick 
82. Urine albumin-creatinine ratio  on freshly voided urine sample 
 
      conversion: 1 mg/mg = 113 mg/mmol 
      it is important to exclude other causes (especially  
infection) when proteinuria is present 
 
83. Urine protein-creatinine ratio  on freshly voided urine sample 




      conversion: 1 mg/mg = 113 mg/mmol 
 
      it is important to exclude other causes (especially  
infection) when proteinuria is present 
 
84. 24 hour urine protein   it is important to exclude other causes (especially  
infection) when proteinuria is present 
 
85. Nephrotic syndrome   criteria: 
heavy proteinuria (  3.5 g/day or protein-  
  creatinine ratio  350 mg/mmol or albumin- 
  creatinine ratio  350 mg/mmol) 
 
           hypoalbuminaemia  
           oedema 
 
86. Plasma/Serum creatinine   exclude other causes for increase in creatinine  
(especially drugs) 
 
87. GFR      MDRD formula (10): 
GFR = 170 x [serum creatinine (mg/dl)]-0.999 x   
              [age]-0.176 x [serum urea (mg/dl]-0.17 x   
              [serum albumin (g/dl)]0.318 x [0.762 if  
              female] x [1.180 if African ancestry] 
       
         units = ml/min per 1.73 m2 
         normal: male = 130 ± 40 
                       female = 120 ± 40 
 
conversion: 
    serum creatinine  -   mg/dl = (mol/l)/88.5 
    serum urea          -  mg/dl = (mmol/l) x 2.8 
          serum albumin    -    g/dl    = (g/l)/10 
 
creatinine clearance not recommended as it is not 
reliable 
 
exclude other causes for decrease in GFR 
(especially drugs) 
 
88. Active urinary sediment   pyuria (> 5 WCC/hpf or > 10 WCC/mm3 (l))  
 
   OR 
 
haematuria (> 5 RBC/hpf or > 10 RBC/mm3 (l)) 
 
   OR 
 
red cell casts  




   OR 
 
white cell casts 
 
exclude other causes (especially infection,  
vaginal bleed, calculi) 
 
89. Histology of active nephritis WHO Classification (1995): (any one)  
   Class III – (a) or (b) subtypes 
   Class IV – (a), (b) or (c) subtypes 
   Class V – (a), (b), (c) or (d) subtypes 
   Vasculitis 
 
    OR 
 
 ISN/RPS Classification (2003) (11): (any one) 
    Class III – (A) or (A/C) subtypes 
    Class IV – (A) or (A/C) subtypes 
    Class V 
    Vasculitis 
  
 within last 3 months 
 






90. Haemoglobin    exclude dietary deficiency & GI blood loss 
91. White cell count    exclude drug-induced cause 
92. Neutrophil count    exclude drug-induced cause 
93. Lymphocyte count 
94. Platelet count    exclude drug-induced cause 
95. TTP     thrombotic thrombocytopaenic purpura 
       
clinical syndrome of micro-angiopathic haemolytic 
anaemia and thrombocytopenia in absence of any 
other identifiable cause 
 
96. Evidence of active haemolysis positive Coombs’ test & evidence of haemolysis 
(raised bilirubin or raised reticulocyte count or 
reduced haptoglobulins or fragmented RBC or 
microspherocytes) 
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These items are required mainly for calculation of GFR 
 
      i.  Weight 
      ii.  African ancestry       
      iii.  Serum urea 
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BILAG-2004 INDEX SCORING 
 











Severe disease activity requiring any of the following treatment: 
 
1. systemic high dose oral glucocorticoids (equivalent to prednisolone > 20  
    mg/day) 
 
2. intravenous pulse glucocorticoids (equivalent to pulse methylprednisolone  
    ≥ 500 mg) 
 
3. systemic immunomodulators (include biologicals, immunoglobulins and  
    plasmapheresis) 
 
4. therapeutic high dose anticoagulation in the presence of high dose steroids  
    or immunomodulators 






Moderate disease activity requiring any of the following treatment: 
 
1. systemic low dose oral glucocorticoids (equivalent to prednisolone ≤ 20  
    mg/day) 
 
2. intramuscular or intra-articular or soft tissue glucocorticoids injection  
    (equivalent to methylprednisolone < 500mg) 
 
3. topical glucocorticoids 
4. topical immunomodulators 
5. antimalarials or thalidomide or prasterone or acitretin 
6. symptomatic therapy 

















System never involved 






Pyrexia recorded as 2 (same), 3 (worse) or 4 (new)  AND  
 
Any 2 or more of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Weight loss 
  Lymphadenopathy/splenomegaly 
  Anorexia 
 
Category B: 
Pyrexia recorded as 2 (same), 3 (worse) or 4 (new)  OR  
 
Any 2 or more of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Weight loss 
  Lymphadenopathy/splenomegaly 
  Anorexia 
 
BUT do not fulfil criteria for Category A 
 
Category C 
Pyrexia recorded as 1 (improving)  OR 
 
One or more of the following recorded as > 0:  
 
Weight loss 
  Lymphadenopathy/Splenomegaly 
  Anorexia 
 























Category A   
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Skin eruption - severe  
Angio-oedema - severe 
  Mucosal ulceration - severe 
  Panniculitis/Bullous lupus - severe 
Major cutaneous vasculitis/thrombosis 
 
Category B  
Any Category A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Skin eruption - mild 
Panniculitis/Bullous lupus - mild 
  Digital infarcts or nodular vasculitis 
  Alopecia - severe 
   
Category C   
Any Category B features recorded as 1 (improving) OR 
 
Any of the following recorded as > 0: 
 
  Angio-oedema - mild 
  Mucosal ulceration - mild 




Category D  
Previous involvement 
 
Category E  
























Acute confusional state 
Psychosis 









Any Category A features recorded as 1 (improving) OR 
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Seizure disorder  
Cerebrovascular disease (not due to vasculitis) 
Cognitive dysfunction 
Movement disorder 
Autonomic disorder  
Lupus headache - severe unremitting 
Headache due to raised intracranial hypertension 
 
Category C 
Any Category B features recorded as 1 (improving) 
 
Category D  
Previous involvement 
 
Category E  
















Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 




Any Category A features recorded as 1 (improving)  OR 
 
Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 




Any Category B features recorded as 1 (improving) OR  
 
Any of the following recorded as > 0: 
 
 Mild Arthritis/Arthralgia/Myalgia 


































Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Myocarditis/Endocarditis + Cardiac failure 
  Arrhythmia 
  New valvular dysfunction 
Cardiac tamponade 
  Pleural effusion with dyspnoea 
  Pulmonary haemorrhage/vasculitis  
Interstitial alveolitis/pneumonitis  





Any Category A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Pleurisy/Pericarditis 
Myocarditis - mild 
 
Category C 



































Intestinal pseudo-obstruction  
Acute lupus cholecystitis 
Acute lupus pancreatitis 
 
Category B 
Any Category A feature recorded as 1 (improving) OR 
 
Any of the following recorded  as 2 (same), 3 (worse) or 4 (new): 
 
Abdominal serositis and/or ascites  
Malabsorption 




Any Category B features recorded as 1 (improving)  
 
Category D  
Previous involvement 
 
Category E   




























Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
Orbital inflammation/myositis/proptosis 
Keratitis - severe 
Posterior uveitis/retinal vasculitis - severe 
Scleritis - severe 
Retinal/choroidal vaso-occlusive disease 
Optic neuritis 
Anterior ischaemic optic neuropathy  
 
Category B 
Any Category A features recorded as 1 (improving) OR  
 
Any of the following recorded as 2 (same), 3 (worse) or 4 (new): 
 
  Keratitis - mild 
Anterior uveitis 
Posterior uveitis/retinal vasculitis - mild 
Scleritis - mild 
 
Category C 
Any Category B features recorded as 1 (improving) OR  
 
Any of the following recorded as > 0: 
 
Episcleritis 



























Two or more of the following providing 1, 4 or 5 is included: 
 
1. Deteriorating proteinuria (severe) defined as   
 
      (a) urine dipstick increased by ≥ 2 levels (used only if other methods of urine protein 
estimation not   
             available); or  
 
      (b) 24 hour urine protein > 1 g that has not decreased (improved) by  25%; or 
      (c) urine protein-creatinine ratio > 100 mg/mmol that has not decreased (improved) by  
25%; or 
      (d) urine albumin-creatinine ratio > 100 mg/mmol that has not decreased (improved) by  
25% 
 
2. Accelerated hypertension  
3. Deteriorating renal function (severe) defined as  
 
      (a) plasma creatinine > 130 mol/l and having risen to > 130% of previous value; or  
      (b) GFR < 80 ml/min per 1.73 m2 and having fallen to < 67% of previous value; or  
      (c) GFR < 50 ml/min per 1.73 m2, and last time was > 50 ml/min per 1.73 m2 or was not 
measured. 
 
4. Active urinary sediment 
5. Histological evidence of active nephritis within last 3 months  
6. Nephrotic syndrome 
 
Category B 
One of the following: 
 
1. One of the Category A feature 
 
2. Proteinuria (that has not fulfilled Category A criteria) 
      (a) urine dipstick which has risen by 1 level to at least 2+ (used only if other methods of 
urine  
             protein estimation not available); or 
 
      (b) 24 hour urine protein ≥ 0.5 g that has not decreased (improved) by  25%; or 
      (c) urine protein-creatinine ratio ≥ 50 mg/mmol that has not decreased (improved) by  25%; 
or 
      (d) urine albumin-creatinine ratio ≥ 50 mg/mmol that has not decreased (improved) by  
25% 
 
3. Plasma creatinine > 130 mol/l and having risen to ≥ 115% but ≤ 130% of previous value 
 
Category C 
One of the following: 




1. Mild/Stable proteinuria defined as 
 
(a) urine dipstick ≥ 1+ but has not fulfilled criteria for Category A & B (used only if other 
methods  
 of urine protein estimation not available); or 
      (b) 24 hour urine protein > 0.25 g but has not fulfilled criteria for Category A & B ; or 
      (c) urine protein-creatinine ratio > 25 mg/mmol but has not fulfilled criteria for Category A 
& B; or  




2. Rising blood pressure (providing the recorded values are > 140/90 mm Hg) which has not 
fulfilled criteria for Category A & B, defined as 
  
(a) systolic rise of ≥ 30 mm Hg; and  






No previous involvement 
 
 
Note: although albumin-creatinine ratio and protein-creatinine ratio are different, we use the 
same cut- 





























TTP recorded as 2 (same), 3 (worse) or 4 (new)   OR 
 
Any of the following: 
   
Evidence of haemolysis and Haemoglobin < 8 g/dl 
Platelet count   < 25 x 109/l 
 
Category B 
TTP recorded as 1 (improving)   OR 
 
Any of the following:  
 
  Evidence of haemolysis and Haemoglobin 8 - 9.9 g/dl 
Haemoglobin   < 8 g/dl (without haemolysis) 
White cell count  < 1.0 x 109/l 
Neutrophil count  < 0.5 x 109/l 
Platelet count   25 - 49 x 109/l 
 
Category C 
Any of the following: 
 
Evidence of haemolysis and Haemoglobin ≥ 10g/dl 
Haemoglobin   8 - 10.9 g/dl (without haemolysis) 
White cell count  1 - 3.9 x 109/l 
Neutrophil count  0.5 - 1.9 x 109/l 
Lymphocyte count  < 1.0 x 109/L 
Platelet count  50 - 149 x 109/l 






No previous involvement 
SLEDAI-2000 index     
Name/ID:                                            Date of Birth:                                 Date of Assessment: 
 
 
SLEDAI-2000 index data collection form 
(Circle in SLEDAI Score column if descriptor is present at the time of the visit or in the   




8 Seizure Recent onset, exclude metabolic, infectious or drug causes 
8 Psychosis Altered ability to function in normal activity due to severe disturbance 
in the perception of reality. Include hallucinations, incoherence, 
marked loose associations, impoverished thought content, marked 
illogical thinking, bizarre, disorganised, or catatonic behaviour. 
Exclude uraemia and drug causes 
8 Organic brain 
syndrome 
Altered mental function with impaired orientation, memory, or other 
intellectual function, with rapid onset and fluctuating clinical features, 
inability to sustain attention to environment, plus at least 2 of the 
following: perceptual disturbance, incoherent speech, insomnia or 
daytime drowsiness, or increased or decreased psychomotor activity. 
Exclude metabolic, infectious or drug causes 
8 Visual disturbance Retinal changes of SLE. Include cytoid bodies, retinal hemorrhages, 
serous exudates or hemorrhages in the choroid, or optic neuritis. 
Exclude hypertension, infection, or drug causes 
8 Cranial nerve 
disorder 
New onset of sensory or motor neuropathy involving cranial nerves 
8 Lupus headache Severe, persistent headache; may be migrainous, but must be non-
responsive to narcotic analgesia 
8 CVA New onset Cerebrovascular accident(s). Exclude arteriosclerosis 
8 Vasculitis Ulceration, gangrene, tender finger nodules, periungual infarction, 
splinter hemorrhages or biopsy or angiogram proof of vasculitis 
4 Arthritis  2 joints with pain and signs of inflammation (i.e. tenderness, swelling 
or effusion) 
4 Myositis Proximal muscle aching/weakness, associated with elevated 
creatinine phosphokinase (CK)/aldolase, or EMG changes or a biopsy 
showing myositis 
4 Urinary casts Heme-granular or RBC casts 
4 Hematuria > 5 RBC/high power field. Exclude stone, infection or other cause 
4 Proteinuria > 0.5 gram/24 hours 
4 Pyuria > 5 WBC/high power field. Exclude infection 
2 Rash Inflammatory type rash 
2 Alopecia Abnormal, patchy or diffuse loss of hair 
2 Mucosal ulcers Oral or nasal ulcerations 
2 Pleurisy Pleuritic chest pain with pleural rub or effusion, or pleural thickening 
2 Pericarditis Pericardial pain with at least 1 of the following: rub, effusion or ECG or 
echocardiogram confirmation 
2 Low complement Decrease in CH50, C3 or C4 below lower limit of normal for testing 
laboratory  
2 Increased DNA 
binding 
Increased DNA binding above normal range for testing laboratory 
1 Fever > 38ºC. Exclude infectious cause 
1 Thrombocytopenia < 100 x 109 platelets/L, exclude drug causes 
1 Leukopenia < 3 x 109 WBC/L, exclude drug causes 
TOTAL SCORE: 
 
Reprinted with permission from The Journal of Rheumatology, Gladman DD et al. Systemic lupus 
erythematosus disease activity index 2000. J Rheumatol 2002;29(2):288. All rights reserved [12].
  
SELENA version of SLEDAI  
SELENA-SLEDAI index data collection form 







1 8 Seizure Recent onset, exclude metabolic, infectious or drug causes 
2 8 Psychosis Altered ability to function in normal activity due to severe disturbance in 
the perception of reality. Include hallucinations, incoherence, marked 
loose associations, impoverished thought content, marked illogical 
thinking, bizarre, disorganised, or catatonic behaviour. Exclude uraemia 
and drug causes 
3 8 Organic brain 
syndrome 
Altered mental function with impaired orientation, memory, or other 
intellectual function, with rapid onset and fluctuating clinical features, 
inability to sustain attention to environment, plus at least 2 of the 
following: perceptual disturbance, incoherent speech, insomnia or 
daytime drowsiness, or increased or decreased psychomotor activity. 
Exclude metabolic, infectious or drug causes 
4 8 Visual disturbance Retinal changes of SLE. Include cytoid bodies, retinal hemorrhages, 
serous exudates or hemorrhages in the choroid, or optic neuritis, 
scleritis or episcleritis. Exclude hypertension, infection, or drug causes 
5 8 Cranial nerve 
disorder 
New onset of sensory or motor neuropathy involving cranial nerves 
6 8 Lupus headache Severe, persistent headache; may be migrainous, but must be non-
responsive to narcotic analgesia  
7 8 CVA New onset cerebrovascular accident(s). Exclude arteriosclerosis 
8 8 Vasculitis Ulceration, gangrene, tender finger nodules, periungual infarction, 
splinter hemorrhages or biopsy or angiogram proof of vasculitis 
9 4 Arthritis > 2 joints with pain and signs of inflammation (i.e. tenderness with 
swelling or effusion) 
10 4 Myositis Proximal muscle aching/weakness, associated with elevated creatinine 
phosphokinase (CK)/aldolase, or EMG changes or a biopsy showing 
myositis 
11 4 Urinary casts Heme-granular or RBC casts 
12 4 Hematuria > 5 RBC/high power field. Exclude stone, infection or other cause 
13 4 Proteinuria New onset or recent increase of more than 0.5 gm/24 hours 
14 4 Pyuria > 5 WBC/high power field. Exclude infection 
15 2 Rash Inflammatory type rash 
16 2 Alopecia Abnormal, patchy or diffuse loss of hair 
17 2 Mucosal ulcers Oral or nasal ulcerations 
18 2 Pleurisy Pleuritic chest pain or pleural rub or effusion, or pleural thickening 
(does not require an objective component if medically convincing) 
19 2 Pericarditis Classic pericardial pain and/or rub, effusion or ECG or echocardiogram 
confirmation (does not require an objective component if medically 
convincing) 
20 2 Low complement Decrease in CH50, C3 or C4 < lower limit of nl for testing laboratory  
21 2 Increased DNA 
binding 
Increased DNA binding above normal range for testing laboratory 
22 1 Fever > 38ºC. Exclude infectious cause 
23 1 Thrombocytopenia < 100 x 109 platelets/L, exclude drug causes 
24 1 Leukopenia < 3 x 109 WBC/L, exclude drug causes 
      
 ______________ Total SCORE 
 
Republished with permission of Elsevier, from Systemic lupus erythematosus: a companion to 
Rheumatology, G Tsokos et al., 1st Edition, © 2007; permission conveyed through Copyright 
Clearance Center, Inc [13].
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